3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Prostatic Neoplasms
7
Colorectal Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Neoplasms
3
Lung Neoplasms
3
Stomatitis
2
Male Urogenital Diseases
2
Cardiovascular Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Vascular Diseases
1
Ulcer
1
Sexual Dysfunction, Physiological
1
Rectal Neoplasms
1
Radiation-induced Injuries in Patients With Rectal Cancer
1
Radiation Injuries
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Non-melanoma Skin Cancer
1
Neurotoxicity Syndromes
1
Myocardial Ischemia
1
Myocardial Infarction
1
Lymphoma, Follicular
1
Heart Diseases
1
Head and Neck Neoplasms
1
Fibrosis
1
Fatigue
1
Eye Diseases
1
Erectile Dysfunction
1
Dyspareunia
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Vitamin E
×
Clear all
NCT00002586
2020-05-15
13-Cis
University of Colorado, Denver
Phase 2
Completed
96 enrolled